Published: June 2001
Publications
Updated HRT Guideline Released
Information on this subject has been updated. Read the most recent information.
Prescriber Update 21: 23-24
June 2001
In May 2001, the New Zealand Guidelines Group (NZGG) launched a new guideline called The Appropriate Prescribing of Hormone Replacement Therapy. It has an evidence-based approach and the key messages are presented below. The NZGG is distributing the Guideline to all prescribers over June/July 2001.
Medsafe would like to reinforce the warning in the Guideline that hormone replacement therapy (HRT) is contraindicated in existing coronary artery disease. This is a required statement in data sheets for HRT medicines. However, at present, some HRT products are indicated for reduction in risk of coronary heart disease (CHD) in women with no current or prior evidence of CHD. In light of the Guideline's advice that HRT is not recommended for the primary prevention of cardiovascular disease, Medsafe will be asking the Medicines Adverse Reactions Committee to comment on the appropriateness of this indication.
The Guideline has received endorsement by the NZGG and the following organisations: The Effective Practice Institute, The Royal NZ College of General Practice, Women's Health Action, NZ Heart Foundation, Australasian Menopause Society, The Cardiac Society of Australia and NZ, Family Planning Association, Osteoporosis NZ, The Royal Australian and New Zealand College of Obstetricians and Gynaecologists, and the College of Nurses Aotearoa NZ.
Contact NZGG for further information
Full details of the evidence found to support the new HRT Guideline is freely available on the NZGG website http://www.nzgg.org.nz. A detailed printed report is also available for purchase for $40 plus post and packaging from info@nzgg.org.nz or ph 04 471 4180.